Access Pharmaceuticals

Access Pharmaceuticals is an emerging pharmaceutical company focused on oncology and diabetes. The company’s ProLindac is a novel DACH platinum-based chemotherapy that recently completed a Phase 2a trial for recurrent ovarian cancer and will soon move into combination trials; ProLindac collaborates with partners in the Far East region. Additionally, Access Pharmaceuticals has a new nucleoside analog, Thiarabine, which will enter Phase 2 leukemia trials this year, as well as preclinical monoclonal antibody (Angiolix) and other preclinical oncology programs.